Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease.

Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77

Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (1996) 1.89

Effects of lymphoma on the peripheral nervous system. J R Soc Med (1994) 1.72

Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood (2014) 1.06

Hodgkin's Lymphoma: A Review of Neurologic Complications. Adv Hematol (2010) 0.97

Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol (2014) 0.89

Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature. Case Rep Oncol (2011) 0.84

Rare association of anti-hu antibody positive paraneoplastic neurological syndrome and transitional cell bladder carcinoma. Case Rep Urol (2012) 0.81

Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna) (2014) 0.80

Paraneoplastic cerebellar degeneration with a circulating antibody against neurons and non-neuronal cells. Acta Neuropathol (1993) 0.79

Paraneoplastic ataxia and dystonia secondary to a malignant fibrous histiocytoma. BMJ Case Rep (2010) 0.75

Central nervous system angiitis in Hodgkin's disease. J Neurol (2013) 0.75

Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain (2000) 7.95

Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol (1983) 5.98

Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer (1982) 4.40

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (2009) 3.68

A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med (1999) 3.58

HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell (1991) 3.33

Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21

Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology (1992) 3.11

Distribution of brain metastases. Arch Neurol (1988) 3.11

Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol (1978) 3.08

Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron (1993) 2.81

Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59

Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol (1990) 2.58

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev (1998) 2.55

Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med (1990) 2.54

Cerebrovascular complications in patients with cancer. Medicine (Baltimore) (1985) 2.39

Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain (1999) 2.35

Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol (1974) 2.33

Effect of brain irradiation on demyelinating lesions. Neurology (1993) 2.21

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19

Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17

Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol (2001) 2.15

Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology (1979) 2.13

Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol (1991) 2.08

Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1987) 2.05

Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol (1998) 1.97

Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors. Cancer (1990) 1.97

Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med (1967) 1.93

Intracranial metastases from systemic cancer. Adv Neurol (1978) 1.92

The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91

Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem (2000) 1.89

Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86

A distinctive glioneuronal tumor of the adult cerebrum with neuropil-like (including "rosetted") islands: report of 4 cases. Am J Surg Pathol (1999) 1.85

Motor neuron syndromes in cancer patients. Ann Neurol (1997) 1.82

MRI changes in intracranial hypotension. Neurology (1993) 1.80

Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79

Subacute encephalitis in acquired immune deficiency syndrome: a postmortem study. Am J Clin Pathol (1984) 1.79

Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain (1997) 1.73

Brachial plexus lesions in patients with cancer: 100 cases. Neurology (1981) 1.70

Herpes simplex encephalitis (HSE) and the immunocompromised: a clinical and autopsy study of HSE in the settings of cancer and human immunodeficiency virus-type 1 infection. Hum Pathol (1998) 1.70

Radiation therapy for brain metastases. Ann Neurol (1980) 1.68

Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol (1980) 1.68

Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology (1988) 1.66

Cerebral metabolic and circulatory responses to induced convulsions in animals. Arch Neurol (1968) 1.66

Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology (1990) 1.65

Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol (1988) 1.63

Metastasis to the base of the skull: clinical findings in 43 patients. Neurology (1981) 1.61

Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurology (1988) 1.59

Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol (1977) 1.58

Steroid myopathy in cancer patients. Neurology (1997) 1.57

Ataxia in epidural spinal cord compression. Neurology (1992) 1.55

Neurologic complications of carcinoid. Neurology (1986) 1.54

Microglia in the giant cell encephalitis of acquired immune deficiency syndrome: proliferation, infection and fusion. Acta Neuropathol (1988) 1.52

Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol (2001) 1.47

Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 1.46

Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol (1979) 1.42

Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology (1992) 1.41

Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1991) 1.41

The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery (1989) 1.40

Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology (1986) 1.39

Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol (1995) 1.37

Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36

Swallow syncope. Report of a case and review of the literature. Neurology (1972) 1.35

Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) (1988) 1.35

Central nervous system infections in patients with cancer. Medicine (Baltimore) (1973) 1.34

Management of central nervous system metastases. Semin Oncol (1977) 1.32

Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology (1994) 1.32

The diagnosis of stupor and coma. Contemp Neurol Ser (1972) 1.26

Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology (1991) 1.26

Headaches in patients with brain tumors: a study of 111 patients. Neurology (1993) 1.25

Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology (1988) 1.22

Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol (1973) 1.22

Hyponatremia in acute polyneuropathy. Four cases with the syndrome of inappropriate secretion of antidiuretic hormone. Arch Neurol (1967) 1.21

Brain metastasis from melanoma. J Neurooncol (1983) 1.21

Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res (1998) 1.20

Cerebellar degeneration-related antigen: a highly conserved neuroectodermal marker mapped to chromosomes X in human and mouse. Proc Natl Acad Sci U S A (1990) 1.19

Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol (1994) 1.19

Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology (1988) 1.19

Human brain tumor transplantation into nude mice. J Natl Cancer Inst (1979) 1.18

T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology (1998) 1.18

Sclerosing epithelioid fibrosarcomas involving the neuraxis: report of three cases. Neurosurgery (2000) 1.18

Spinal subdural hematomas complicating lumbar puncture. Arch Neurol (1974) 1.17

Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol (1996) 1.16

Treatment of experimental spinal cord compression caused by extradural neoplasms. J Neurosurg (1977) 1.15

Extraneural metastases of infratentorial glioblastoma multiforme to the peritoneal cavity. Cancer (1992) 1.14

Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology (1995) 1.11